Piper Jaffray Cos. upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) from a neutral rating to an overweight rating in a research note published on Monday morning.

SRPT has been the topic of a number of other research reports. Leerink Swann reiterated an underperform rating and set a $5.00 target price on shares of Sarepta Therapeutics in a report on Thursday, August 4th. Vetr cut Sarepta Therapeutics from a hold rating to a sell rating and set a $17.28 price objective on the stock. in a report on Monday, May 23rd. Robert W. Baird restated an outperform rating and set a $23.00 price objective on shares of Sarepta Therapeutics in a report on Monday, July 18th. Oppenheimer Holdings Inc. restated an outperform rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, July 26th. Finally, JMP Securities restated an underperform rating and set a $10.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, September 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of Buy and a consensus price target of $48.70.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.97 on Monday. The stock’s market cap is $2.92 billion. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $61.60. The company has a 50 day moving average price of $30.01 and a 200 day moving average price of $21.91.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the previous year, the business posted ($0.87) earnings per share. Analysts anticipate that Sarepta Therapeutics will post ($4.17) earnings per share for the current fiscal year.

In related news, CEO Edward M. Md Kaye sold 24,352 shares of Sarepta Therapeutics stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,217,600.00. Following the completion of the transaction, the chief executive officer now directly owns 89,983 shares in the company, valued at $4,499,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jayant Aphale sold 35,000 shares of Sarepta Therapeutics stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at $1,074,500. The disclosure for this sale can be found here. 10.90% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the company. National Planning Corp increased its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Rhumbline Advisers increased its position in Sarepta Therapeutics by 1.6% in the second quarter. Rhumbline Advisers now owns 46,719 shares of the company’s stock worth $891,000 after buying an additional 721 shares during the period. Teacher Retirement System of Texas increased its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. First Allied Advisory Services Inc. increased its position in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the period. Finally, LGL Partners LLC increased its position in Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares during the period. Institutional investors and hedge funds own 72.09% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.